545 related articles for article (PubMed ID: 31447854)
1. Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases.
Szilveszter KP; Németh T; Mócsai A
Front Immunol; 2019; 10():1862. PubMed ID: 31447854
[TBL] [Abstract][Full Text] [Related]
2. Targeting the Janus Kinase Family in Autoimmune Skin Diseases.
Howell MD; Kuo FI; Smith PA
Front Immunol; 2019; 10():2342. PubMed ID: 31649667
[TBL] [Abstract][Full Text] [Related]
3. JAK inhibitor: Introduction.
Raychaudhuri SP; Raychaudhuri SK
Indian J Dermatol Venereol Leprol; 2023; 89(5):688-690. PubMed ID: 37609754
[TBL] [Abstract][Full Text] [Related]
4. Targeting JAK/STAT signalling in inflammatory skin diseases with small molecule inhibitors.
Welsch K; Holstein J; Laurence A; Ghoreschi K
Eur J Immunol; 2017 Jul; 47(7):1096-1107. PubMed ID: 28555727
[TBL] [Abstract][Full Text] [Related]
5. JAK/STAT pathway modulation: Does it work in dermatology?
Gündüz Ö
Dermatol Ther; 2019 May; 32(3):e12903. PubMed ID: 30964573
[TBL] [Abstract][Full Text] [Related]
6. New small molecules in dermatology: for the autoimmunity, inflammation and beyond.
Criado PR; Lorenzini D; Miot HA; Bueno-Filho R; Carneiro FRO; Ianhez M
Inflamm Res; 2023 Jun; 72(6):1257-1274. PubMed ID: 37212867
[TBL] [Abstract][Full Text] [Related]
7. Inhibitors of switch kinase 'spleen tyrosine kinase' in inflammation and immune-mediated disorders: a review.
Kaur M; Singh M; Silakari O
Eur J Med Chem; 2013 Sep; 67():434-46. PubMed ID: 23917087
[TBL] [Abstract][Full Text] [Related]
8. Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.
Patterson H; Nibbs R; McInnes I; Siebert S
Clin Exp Immunol; 2014 Apr; 176(1):1-10. PubMed ID: 24313320
[TBL] [Abstract][Full Text] [Related]
9. The emerging role of Janus kinase inhibitors in the treatment of autoimmune and inflammatory diseases.
Damsky W; Peterson D; Ramseier J; Al-Bawardy B; Chun H; Proctor D; Strand V; Flavell RA; King B
J Allergy Clin Immunol; 2021 Mar; 147(3):814-826. PubMed ID: 33129886
[TBL] [Abstract][Full Text] [Related]
10. An insight into JAK-STAT signalling in dermatology.
Palanivel JA; Macbeth AE; Chetty NC; Levell NJ
Clin Exp Dermatol; 2014 Jun; 39(4):513-8. PubMed ID: 24825142
[TBL] [Abstract][Full Text] [Related]
11. The use of selective pharmacological inhibitors to delineate signal transduction pathways activated during complement receptor-mediated degranulation in chicken heterophils.
Kogut MH; Lowry VK; Farnell M
Int Immunopharmacol; 2003 May; 3(5):693-706. PubMed ID: 12757738
[TBL] [Abstract][Full Text] [Related]
12. Genetic and pharmacological analyses of involvement of Src-family, Syk and Btk tyrosine kinases in platelet shape change. Src-kinases mediate integrin alphaIIb beta3 inside-out signalling during shape change.
Bauer M; Maschberger P; Quek L; Briddon SJ; Dash D; Weiss M; Watson SP; Siess W
Thromb Haemost; 2001 Feb; 85(2):331-40. PubMed ID: 11246557
[TBL] [Abstract][Full Text] [Related]
13. [Involvement of Syk in pathology of systemic autoimmune disease].
Iwata S; Yamaoka K; Niiro H; Nakano K; Wang SP; Saito K; Akashi K; Tanaka Y
Nihon Rinsho Meneki Gakkai Kaishi; 2012; 35(1):56-61. PubMed ID: 22374444
[TBL] [Abstract][Full Text] [Related]
14. Protein tyrosine kinases Syk and ZAP-70 display distinct requirements for Src family kinases in immune response receptor signal transduction.
Zoller KE; MacNeil IA; Brugge JS
J Immunol; 1997 Feb; 158(4):1650-9. PubMed ID: 9029101
[TBL] [Abstract][Full Text] [Related]
15. IL-3 signaling and the role of Src kinases, JAKs and STATs: a covert liaison unveiled.
Reddy EP; Korapati A; Chaturvedi P; Rane S
Oncogene; 2000 May; 19(21):2532-47. PubMed ID: 10851052
[TBL] [Abstract][Full Text] [Related]
16. Tyrosine kinase inhibitors as potential drugs for B-cell lymphoid malignancies and autoimmune disorders.
Robak T; Robak E
Expert Opin Investig Drugs; 2012 Jul; 21(7):921-47. PubMed ID: 22612424
[TBL] [Abstract][Full Text] [Related]
17. TAS05567, a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor, Abrogates Immunoglobulin-Mediated Autoimmune and Allergic Reactions in Rodent Models.
Hayashi H; Kaneko R; Demizu S; Akasaka D; Tayama M; Harada T; Irie H; Ogino Y; Fujino N; Sasaki E
J Pharmacol Exp Ther; 2018 Jul; 366(1):84-95. PubMed ID: 29728446
[TBL] [Abstract][Full Text] [Related]
18. JAK3 as an Emerging Target for Topical Treatment of Inflammatory Skin Diseases.
Alves de Medeiros AK; Speeckaert R; Desmet E; Van Gele M; De Schepper S; Lambert J
PLoS One; 2016; 11(10):e0164080. PubMed ID: 27711196
[TBL] [Abstract][Full Text] [Related]
19. Syk and Lyn mediate distinct Syk phosphorylation events in FcɛRI-signal transduction: implications for regulation of IgE-mediated degranulation.
Sanderson MP; Wex E; Kono T; Uto K; Schnapp A
Mol Immunol; 2010; 48(1-3):171-8. PubMed ID: 20828828
[TBL] [Abstract][Full Text] [Related]
20. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases.
Clark JD; Flanagan ME; Telliez JB
J Med Chem; 2014 Jun; 57(12):5023-38. PubMed ID: 24417533
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
